A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.docVIP

Fernández et al. BMC Pediatrics 2010, 10:38 /1471-2431/10/38 RESEARCH ARTICLE Open Access A phase 2, randomized, double-blind safety and Research article pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season Pilar Fernández1, Adrian Trenholme2, Katia Abarca3, M Pamela Griffin*4, Micki Hultquist4, Brian Harris4, Genevieve A Losonsky4 for the Motavizumab Study Group Abstract Background: Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia